Items tagged with Treatment
Union position on injectable-free regimens for the treatment of drug-resistant TB (post)
South Africa recently announced it would be providing all oral-regimens to a majority of persons with rifampicin-resistant tuberculosis (RR-TB)[1] by replacing injectable medicines with bedaquiline. This decision was based on a retrospective cohort analysis from the country showing improved treatment success and reduction of mortality when bedaquiline was given to persons with drug resistant-TB (DR-TB) under programmatic conditions (https://www.thelancet.com/journals/lanres/onlineFirst).
New TB drugs are safe, effective alternatives (post)
New interim findings from endTB indicate bedaquiline and delamanid could benefit many more patients.
Latent TB treatment: Shorter is better (post)
Game-changing study on treatment of latent TB shows a novel, short therapy is safer and more effective in children and adults than standard therapy.
A pan-TB regimen: The debate continues (post)
Multidrug-resistant tuberculosis (MDR-TB) treatment is evolving. Last month the South Africa National Tuberculosis Program decided to prioritize oral bedaqualine for all rifampin-resistant TB (RR-TB) in place of — the often more toxic — injectable drugs. The question of whether a package of novel oral medications as part of a universal regimen can replace the current approach to TB management divides the TB therapeutic community. In this second article we further explore this divergence of opinion.
TAG's TB Activist's Toolkits now available in Spanish (post)
In addition to the Russian translations, Spanish translations of An Activist’s Guide to Tuberculosis Diagnostic Tools and An Activist’s Guide to Tuberculosis Drugs are now also available.
South Africa strikes deal on new TB drug as WHO revisits guidance (post)
AMSTERDAM — The World Health Organization could soon start promoting a new tuberculosis drug that is now more affordable after South Africa brokered a deal with a pharmaceutical company to slash the price by half.
Why India must discard fear, give some TB patients ‘game-changing’ drug (post)
Like South Africa, India should immediately make available the tuberculosis (TB) drug bedaquiline – till now used as a drug of last resort – to nearly 147,000 Indians with a multidrug-resistant version of the disease, a leading South African TB-HIV researcher told IndiaSpend.
Analysis: Not all good news in new WHO MDR-TB recommendations (post)
In a move that could help save the hearing of thousands of people with TB, the World Health Organisation (WHO) is advising wider use of newer and repurposed drugs, bedaquiline and linezolid in place of injections that cause deafness. Rather perplexingly, the WHO is however also maintaining its recommendation for a shorter and cheaper, but much less impressive treatment regimen and advised that the new South African regimen should only be used under conditions of operational research.
Study shows children with multidrug-resistant TB can be treated (post)
The results of a large, international systematic review published in the journal PLOS Medicine show that tuberculosis treatment is successful in children with multidrug-resistant tuberculosis (MDR-TB). The study was used to inform the World Health Organization guidelines on treatment of MDR-TB in children.
Risk for relapse in drug-susceptible TB cases rises with MIC values (post)
The risk that patients with drug-susceptible tuberculosis will experience a relapse appears greater when minimum inhibitory concentration, or MIC, values are higher, according to study findings published in The New England Journal of Medicine.
Page 41 of 108 · Total posts: 0
←First 40 41 42 Last→